# OnCo record chordoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/chordoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "chordoma" ;
  schema:name "Chordoma"@en ;
  schema:alternateName "Childhood chordoma"@en, "Clival chordoma"@en, "Sacral chordoma"@en ;
  schema:description "Chordoma is a slow-growing bone cancer (a sarcoma) of the skull base and spine that arises from leftover embryonic notochord cells. Complete surgery followed by high-dose proton or carbon-ion radiotherapy controls most tumours, and the whole disease depends on a single transcription factor, brachyury, which vaccines and degraders are now trying to hit."@en ;
  schema:url <https://onco.cc/cancers/chordoma/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chordoma> ;
  schema:citation <https://www.cancer.gov/types/bone>, <https://doi.org/10.1016/S1470-2045(14)71190-8>, <https://www.chordomafoundation.org/> ;
  onco:tag "nci-coverage", "rare", "sarcoma", "paediatric" ;
  onco:related <https://onco.cc/cancers/chondrosarcoma/>, <https://onco.cc/cancers/osteosarcoma/>, <https://onco.cc/cancers/ewing-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/pdgfra/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/drugs/gi-6301/> ;
  onco:pathways <https://onco.cc/pathways/swi-snf-chromatin/>, <https://onco.cc/pathways/transcription-addiction/> ;
  onco:terms <https://onco.cc/terms/rare-cancers/> ;
  onco:trials <https://onco.cc/trials/regobone/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-undruggable-targets/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-stacchiotti-lancet-oncol/> ;
  onco:pipeline <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/afatinib/> ;
  onco:standardOfCare <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/carbon-ion/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/technologies/kinase-inhibitors/> .